<DOC>
	<DOCNO>NCT01914796</DOCNO>
	<brief_summary>This study determine safety tolerability PF-06412562 give orally healthy volunteer . To determine optimal dose future study , concentration drug time determine periodic blood sample . The rate eye blink measure indicator PF-06412562 action receptor interest brain .</brief_summary>
	<brief_title>A Phase I Trial Investigate Safety Tolerability PF-06412562</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subject nonchildbearing potential age 18 55 year Female subject non childbearing potential meet least one follow criterion : Achieved postmenopausal status , define : cessation regular menses least 12 consecutive month alternative pathological physiological cause ; serum follicle stimulate hormone ( FSH ) level confirm postmenopausal status ; Have undergone document hysterectomy and/or bilateral oophorectomy ; Have medically confirm ovarian failure . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Any condition possibly affect drug absorption .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Randomized</keyword>
	<keyword>Double Blind</keyword>
	<keyword>Placebo-Controlled</keyword>
	<keyword>Single-Dose Escalation</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>PK</keyword>
	<keyword>PD</keyword>
	<keyword>PF-06412562</keyword>
</DOC>